What is The NeuroCircuit?

The NeuroCircuit is a weekly briefing covering the frontiers of neurotechnology — brain-computer interfaces, biosensing, neuroengineering, and the science and systems behind them. Every issue filters the noise so you get what actually matters, without the hype.

How often is it published?

Every week. The Weekly Signal drops on Saturdays.

What topics does it cover?

BCIs, closed-loop neuromodulation, neural implants, EEG and biosignal processing, neurorehabilitation, ethics and policy, clinical trials, and emerging tools at the intersection of neuroscience and engineering. If it's moving the field forward — or raising the right questions — it's in scope.

Who writes it?

Ricardo Albornoz — a software engineer and IT analyst with a background in computer science, biosignal pipelines, and a long obsession with how the brain works. The NeuroCircuit is independent, unsponsored, and written from genuine curiosity about where this field is going.

Is it free?

Yes. Subscribe and it lands in your inbox every week at no cost.

Do I need a technical background to understand the content?

Not at all. The NeuroCircuit is written to be accessible to anyone seriously curious about neurotechnology — whether you're an engineer, a clinician, a researcher, or someone who just found out BCIs exist and can't stop thinking about them. Technical depth is there for those who want it, but it's never a barrier.

Can I suggest a story or research tip?

Yes, please. If you've come across something worth covering — a new trial, a paper, a company, a development most people are missing — send it through the contact form. Tips from readers are genuinely valuable.

Do you cover DIY / consumer neurotech or only clinical research?

Both. The field spans everything from FDA-cleared implants to open-source EEG projects, and the boundaries between them are getting blurrier. Coverage follows the signal, not the price tag.

How do you separate signal from hype?

By going closer to the source. Press releases get checked against preprints. Bold claims get contextualized against trial data and peer review. The goal isn't cynicism — genuine breakthroughs deserve recognition — but clarity. If something is promising but unproven, that distinction matters and it'll be stated clearly.